Combined KRAS(G12C) and SOS1 inhibition enhances and extends the anti-tumor response in KRAS(G12C)-driven cancers by addressing intrinsic and acquired resistance

Efforts to improve the anti-tumor response to KRAS(G12C) targeted therapy have benefited from leveraging combination approaches. Here, we compare the anti-tumor response induced by the SOS1-KRAS interaction inhibitor, BI-3406, combined with a KRAS(G12C) inhibitor (KRAS(G12C)i) to those induced by KR...

Descripción completa

Detalles Bibliográficos
Autores principales: Thatikonda, Venu, Lu, Hengyu, Jurado, Sabine, Kostyrko, Kaja, Bristow, Christopher A., Bosch, Karin, Feng, Ningping, Gao, Sisi, Gerlach, Daniel, Gmachl, Michael, Lieb, Simone, Jeschko, Astrid, Machado, Annette A., Marszalek, Ethan D., Mahendra, Mikhila, Jaeger, Philipp A., Sorokin, Alexey, Strauss, Sandra, Trapani, Francesca, Kopetz, Scott, Vellano, Christopher P., Petronczki, Mark, Kraut, Norbert, Heffernan, Timothy P., Marszalek, Joseph R., Pearson, Mark, Waizenegger, Irene, Hofmann, Marco H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900819/
https://www.ncbi.nlm.nih.gov/pubmed/36747713
http://dx.doi.org/10.1101/2023.01.23.525210

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9900819/
https://www.ncbi.nlm.nih.gov/pubmed/36747713
http://dx.doi.org/10.1101/2023.01.23.525210

Ejemplares similares